CymaBay Therapeutics (CBAY) Misses Q4 EPS by 40c
Tweet
Share
E-mailGet Alerts CBAY Hot Sheet
Join SI Premium – FREE
CymaBay Therapeutics (NASDAQ: CBAY) reported Q4 EPS of ($0.87), $0.40 worse than the analyst estimate of ($0.47).
For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
- Snail, Inc. (SNAL) Reports Q3 Loss of $0.36
- RideNow Group, Inc. (RDNW) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
